Transcriptomics

Dataset Information

0

Next Generation Sequencing Analysis of Pparafl/fl and PparaΔIE intestinal transcriptomes


ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic diseases globally and nonalcoholic steatohepatitis is its progressive stage with limited therapeutic options. Here a role for intestinal peroxisome proliferator-activated receptor α (PPARα)-fatty acid binding protein 1 (FABP1) in obesity-associated metabolic syndrome, fatty liver and nonalcoholic steatohepatitis via modulating dietary fat absorption was uncovered. Intestinal PPARα is highly activated accompanied by marked upregulation of FABP1 by high-fat diet (HFD) in mice and obese humans. Intestine-specific PPARα or FABP1 disruption in mice decreases HFD-induced obesity, fatty liver and nonalcoholic steatohepatitis and intestinal PPARα disruption fails to further decrease obesity and NASH. Chemical PPARα antagonism improves metabolic disorders depending on the presence of intestinal PPARα or FABP1. Translationally, GW6471 decreases human PPARα-driven intestinal fatty acid uptake and therapeutically improves obesity in PPARA-humanized, but not Ppara-null, mice. These results suggest that intestinal PPARα-FABP1 axis could be a therapeutic target for NASH.

ORGANISM(S): Mus musculus

PROVIDER: GSE190140 | GEO | 2022/09/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2019-03-30 | GSE129080 | GEO
2023-08-18 | GSE205845 | GEO
2023-08-18 | GSE205846 | GEO
2013-04-02 | E-GEOD-37031 | biostudies-arrayexpress
2024-05-29 | GSE255356 | GEO
2023-03-23 | PXD040233 | Pride
2022-04-05 | GSE174478 | GEO
2017-07-21 | GSE66676 | GEO
2019-07-31 | GSE134146 | GEO
2021-05-31 | GSE167523 | GEO